246 related articles for article (PubMed ID: 29848015)
1. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
[TBL] [Abstract][Full Text] [Related]
2. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
3. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
[TBL] [Abstract][Full Text] [Related]
4. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
[TBL] [Abstract][Full Text] [Related]
5. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
[TBL] [Abstract][Full Text] [Related]
6. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
7. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
[TBL] [Abstract][Full Text] [Related]
8. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
[TBL] [Abstract][Full Text] [Related]
9. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
[TBL] [Abstract][Full Text] [Related]
10. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
Chen JH; Yu H; Lin M; Mehta RS; Su MY
Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
[TBL] [Abstract][Full Text] [Related]
11. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications.
Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY
Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651
[TBL] [Abstract][Full Text] [Related]
12. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C
Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135
[TBL] [Abstract][Full Text] [Related]
13. Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer.
Lim Y; Ko ES; Han BK; Ko EY; Choi JS; Lee JE; Lee SK
Breast Cancer Res Treat; 2017 Jun; 163(3):573-586. PubMed ID: 28349273
[TBL] [Abstract][Full Text] [Related]
14. Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.
You C; Peng W; Zhi W; He M; Liu G; Xie L; Jiang L; Hu X; Shen X; Gu Y
Transl Oncol; 2017 Oct; 10(5):786-792. PubMed ID: 28806712
[TBL] [Abstract][Full Text] [Related]
15. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review.
Li X; Yan F
Cancer Imaging; 2024 Mar; 24(1):35. PubMed ID: 38462607
[TBL] [Abstract][Full Text] [Related]
17. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of background parenchymal enhancement in breast contrast-enhanced ultrasound with Sonazoid
Haga M; Hirai T; Nakai T; Kobayashi T; Nakamura T; Marugami A; Ito T; Takewa M; Marugami N; Kichikawa K
J Med Ultrason (2001); 2020 Oct; 47(4):591-601. PubMed ID: 32989596
[TBL] [Abstract][Full Text] [Related]
19. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy.
Hilal T; Covington M; Kosiorek HE; Zwart C; Ocal IT; Pockaj BA; Northfelt DW; Patel BK
Breast J; 2018 Nov; 24(6):1010-1014. PubMed ID: 30066421
[TBL] [Abstract][Full Text] [Related]
20. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]